Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-08-04
1997-12-16
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514573, 514913, A61K 31215, A61K 3119
Patent
active
056985983
ABSTRACT:
The invention relates to the use of EP.sub.2 receptor agonists as potent ocular hypotensives, and are particularly suitable for the management of glaucoma. In particular said compounds are represented by the formulae: ##STR1## wherein the broken line attachment to the cyclopentane ring or the omega chain indicates the .alpha. configuration and the solid line attachment to the cyclopentane ring or the omega chain indicates the .beta. configuration, R is hydrogen or a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.1 wherein m is 0-10, and R.sub.1 is an aliphatic ring having from about 3 to about 7 carbon atoms, or an aryl or heteroaryl ring having from about 4 to about 10 carbon atoms and wherein the heteroatom is selected from the group consisting of N, O and S.
REFERENCES:
patent: 4494274 (1985-01-01), Chan et al.
patent: 4599353 (1986-07-01), Bito
patent: 5034413 (1991-07-01), Chan et al.
Starr. M.S., "Further Studies on the Effect of Prostalgnadin on Intraocular Pressure in the Rabbit", Exp. Eye Research, 1971, 11, pp. 170-177.
Bito, L.Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents," Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson, et al., "PGF.sub.2.alpha. Increases Uveoscleral Outflow", Invest. Ophthalmol. Vis. Sci. (Suppl), 284, 1987.
Siebold, et al., "Esterified prostaglandin shows `potent` promise", Prodrug 5 3, 1989.
Bito, L.Z., "Prostaglandins, Old Concepts and New Perspectives", Arch. Ophthalmol. 105, 1036, 1987.
Coleman, R.A., et al., "Prostanoids and their Receptors", Comprehensive Medicinal Chemistry, vol. 3, pp. 643-714, 1990.
Woodward et al, "Identification of 19 (R) -OH Prostaglandin E.sub.2 as a Selective Prostanoid EP.sub.2 -Receptor Agonist", Prostaglandins, pp. 371-383, 1993.
Nials et al, "AH13205, A Selective Prostanoid EP.sub.2 -receptor Agonist", Cardiovascular Drug Reviews, vol. 11, No. 2, pp. 165-179.
Weeldon et al, Br. J. Pharmacol (1993), 108(4), 1051-4.
Nials et al, Br. J. Pharmacol, 102, 24P (1991).
HCAplus, 112: 112735, 1989--Woodward et al.
Allergan
Baran Robert J.
Fay Zohreh
Lambert Howard R.
Voet Martin A.
LandOfFree
EP.sub.2 -receptor agonists as agents for lowering intraocular p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EP.sub.2 -receptor agonists as agents for lowering intraocular p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP.sub.2 -receptor agonists as agents for lowering intraocular p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-206849